27,315 Shares in Hologic, Inc. (NASDAQ:HOLX) Purchased by Centiva Capital LP

Centiva Capital LP acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 27,315 shares of the medical equipment provider's stock, valued at approximately $1,969,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in HOLX. Barclays PLC boosted its position in Hologic by 47.6% during the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock worth $58,507,000 after acquiring an additional 231,578 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Hologic during the third quarter worth approximately $93,000. Tidal Investments LLC boosted its holdings in shares of Hologic by 60.1% during the third quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider's stock worth $1,250,000 after purchasing an additional 5,764 shares during the period. Franklin Resources Inc. grew its position in Hologic by 171.7% during the third quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider's stock valued at $22,714,000 after purchasing an additional 175,855 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in Hologic by 3.6% in the 3rd quarter. Principal Financial Group Inc. now owns 269,546 shares of the medical equipment provider's stock valued at $21,957,000 after buying an additional 9,419 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Hologic

In other news, Director Martin D. Madaus acquired 5,445 shares of the stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the transaction, the director now owns 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.88% of the company's stock.

Hologic Stock Performance

NASDAQ:HOLX traded up $0.56 during mid-day trading on Friday, hitting $56.74. 3,258,934 shares of the company's stock traded hands, compared to its average volume of 2,090,002. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm has a 50 day moving average of $59.43 and a two-hundred day moving average of $68.34. The firm has a market capitalization of $12.73 billion, a price-to-earnings ratio of 17.90, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Hologic's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the business earned $1.03 earnings per share. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Royal Bank of Canada dropped their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Evercore ISI dropped their target price on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. Citigroup cut their price target on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. StockNews.com cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Friday, May 2nd. Twelve investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $79.85.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.